<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39347210</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Computational Investigations to Identify Potent Natural Flavonoid Inhibitors of the Nonstructural Protein (NSP) 16/10 Complex Against Coronavirus.</ArticleTitle><Pagination><StartPage>e68098</StartPage><MedlinePgn>e68098</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68098</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68098</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Globally, the viral pandemic has spread rapidly, resulting in widespread infections. The coronavirus family (CoVs) is one of the various viral families capable of infecting mammals, causing diseases related to the gastrointestinal, neurological, and respiratory systems. Flavonoid compounds have been identified as potentially effective antiviral agents, specifically targeting the virus's nonstructural protein (NSP) 16/10. Flavonoids have also been shown to inhibit virus replication and viral attachment to host cells, making them a promising candidate for antiviral treatment. Further research is needed to understand the full potential of flavonoids as antiviral agents.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">This study investigated natural compounds derived from medicinal plants using in silico screening. In addition to assessing drug-likeness, pharmacokinetics, docking, molecular dynamics simulation, bioavailability assessment, and exploration of molecular targets, the screening process entailed analyses of molecular targets and bioavailability. The molecular properties and potential antiviral efficacy of these phytochemical candidates were determined by analyzing them as drug candidates. The results of the study showed that these compounds had potential antiviral activity and could be developed as therapeutic agents. Furthermore, the study showed that the compounds had good bioavailability, suggesting that they are suitable for use as therapeutic agents.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">An in silico method was used to identify flavonoid compounds for potent antiviral drug molecules against the coronavirus protein complex NSP16/10 protein. The NSP16/10 complex protein binding energy values were -6.14 for isoquercetin, -6.902 for narirutin, -6.052 for myricetin, -7.10 for hesperidin, -4.392 for silibinin, -3.997 for baicalein, -3.712 for taxifolin, and -3.321 for petunidin. Molecular dynamics simulations showed that isoquercetin, hesperidin, and narirutin flavonoids interacted with the COVID-19 virus protein complex NSP16/10 protease up to 100 nanoseconds.</AbstractText><CopyrightInformation>Copyright © 2024, Tamil Selvan et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamil Selvan</LastName><ForeName>Silambarasan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS) Saveetha University, Chennai, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganta</LastName><ForeName>Gurupavan Kumar</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Biochemistry, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS) Saveetha University, Chennai, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">flavonoids</Keyword><Keyword MajorTopicYN="N">in silico</Keyword><Keyword MajorTopicYN="N">molecular docking</Keyword><Keyword MajorTopicYN="N">molecular dynamics simulation</Keyword></KeywordList><CoiStatement>Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39347210</ArticleId><ArticleId IdType="pmc">PMC11438528</ArticleId><ArticleId IdType="doi">10.7759/cureus.68098</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Ren LL, Wang YM, Wu ZQ, et al. Chin Med J (Engl) 2020;133:1015–1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147275</ArticleId><ArticleId IdType="pubmed">32004165</ArticleId></ArticleIdList></Reference><Reference><Citation>Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, Bloom JD. Cell Host Microbe. 2021;29:463–476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Wu A, Peng Y, Huang B, et al. Cell Host Microbe. 2020;27:325–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154514</ArticleId><ArticleId IdType="pubmed">32035028</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. Decroly E, Imbert I, Coutard B, et al.  https://pubmed.ncbi.nlm.nih.gov/18417574/ J Virol. 2008;82:8071–8084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519555</ArticleId><ArticleId IdType="pubmed">18417574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulam herbs: a review on the medicinal properties of Anacardium occidentale and Barrington racemose. Chan EW, Baba S, Chan HT, et al. J Appl Pharm Sci. 2017;7:241–247.</Citation></Reference><Reference><Citation>The essential medicinal chemistry of curcumin. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. J Med Chem. 2017;60:1620–1637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346970</ArticleId><ArticleId IdType="pubmed">28074653</ArticleId></ArticleIdList></Reference><Reference><Citation>In vitro antiviral activity of twenty-seven medicinal plant extracts from Southwest Nigeria against three serotypes of echoviruses. Ogbole OO, Akinleye TE, Segun PA, Faleye TC, Adeniji AJ. Virol J. 2018;15:110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052623</ArticleId><ArticleId IdType="pubmed">30021589</ArticleId></ArticleIdList></Reference><Reference><Citation>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Daina A, Michielin O, Zoete V. https://doi.org/10.1038/srep42717. Sci Rep. 2017;7:42717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Lipinski CA, Lombardo F, Dominy BW, et al. Adv Drug Deliv Rev. 1997;23:3–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus. Umar HI, Siraj B, Ajayi A, Jimoh TO, Chukwuemeka PO. J Genet Eng Biotechnol. 2021;19:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7829640</ArticleId><ArticleId IdType="pubmed">33492492</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of natural compounds against the SARS-CoV-2 main-protease. C S, S DK, Ragunathan V, Tiwari P, A S, P BD. J Biomol Struct Dyn. 2022;40:585–611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573242</ArticleId><ArticleId IdType="pubmed">32897178</ArticleId></ArticleIdList></Reference><Reference><Citation>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. Ghose AK, Viswanadhan VN, Wendoloski JJ. https://doi.org/10.1021/cc9800071. J Comb Chem. 1999;1:55–68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746014</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral activity of some Nigerian medicinal plant extracts. Kudi AC, Myint SH. J Ethnopharmacol. 1999;68:289–294.</Citation><ArticleIdList><ArticleId IdType="pubmed">10624890</ArticleId></ArticleIdList></Reference><Reference><Citation>Computational investigation of structural dynamics of SARS-CoV-2 methyltransferase-stimulatory factor heterodimer nsp16/nsp10 bound to the cofactor SAM. Sk MF, Jonniya NA, Roy R, Poddar S, Kar P. https://doi.org/10.3389/fmolb.2020.590165. Front Mol Biosci. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732651</ArticleId><ArticleId IdType="pubmed">33330626</ArticleId></ArticleIdList></Reference><Reference><Citation>The crystal structure of nsp10-nsp16 heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine. Rosas-Lemus M, Minasov G, Shuvalova L, et al. bioRxiv. 2020</Citation></Reference><Reference><Citation>A fast shake algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. Kräutler V, van Gunsteren WF, Hünenberger PH. https://doi.org/10.1002/1096-987X(20010415)22:5&lt;501::AID-JCC1021&gt;3.0.CO;2-V J Comput Chem. 2001;22:501–508.</Citation></Reference><Reference><Citation>Mechanisms modified by (-)-epicatechin and taxifolin relevant for the treatment of hypertension and viral infection: knowledge from preclinical studies. Bernatova I, Liskova S. Antioxidants (Basel) 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8002320</ArticleId><ArticleId IdType="pubmed">33809620</ArticleId></ArticleIdList></Reference><Reference><Citation>The significance of ayurvedic medicinal plants. Kumar S, Dobos GJ, Rampp T. J Evid Based Complementary Altern Med. 2017;22:494–501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5871155</ArticleId><ArticleId IdType="pubmed">27707902</ArticleId></ArticleIdList></Reference><Reference><Citation>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. https://doi.org/10.1016/j.antiviral.2006.04.014. Antiviral Res. 2007;74:92–101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114332</ArticleId><ArticleId IdType="pubmed">16730806</ArticleId></ArticleIdList></Reference><Reference><Citation>In silico approach for identification of natural compounds as potential COVID 19 main protease (M(pro)) inhibitors. Chaturvedi M, Nagre K, Yadav JP. https://link.springer.com/article/10.1007/s13337-021-00701-7. Virusdisease. 2021;32:325–329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214915</ArticleId><ArticleId IdType="pubmed">34179304</ArticleId></ArticleIdList></Reference><Reference><Citation>Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say? Agoni C, Olotu FA, Ramharack P, Soliman ME. J Mol Model. 2020;26:120.</Citation><ArticleIdList><ArticleId IdType="pubmed">32382800</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. Shi TH, Huang YL, Chen CC, et al.  https://doi.org/10.1016/j.bbrc.2020.08.086. Biochem Biophys Res Commun. 2020;533:467–473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447262</ArticleId><ArticleId IdType="pubmed">32977949</ArticleId></ArticleIdList></Reference><Reference><Citation>In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes. Shaldam MA, Yahya G, Mohamed NH, Abdel-Daim MM, Al Naggar Y. https://link.springer.com/article/10.1007/s11356-021-14195-9. Environ Sci Pollut Res Int. 2021;28:40507–40514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088405</ArticleId><ArticleId IdType="pubmed">33934306</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. Krafcikova P, Silhan J, Nencka R, Boura E. Nat Commun. 2020;11:3717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381658</ArticleId><ArticleId IdType="pubmed">32709887</ArticleId></ArticleIdList></Reference><Reference><Citation>Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods. Hossain A, Rahman ME, Rahman MS, et al.  https://www.sciencedirect.com/science/article/pii/S0010482523002500. Comput Biol Med. 2023;157:106785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10008098</ArticleId><ArticleId IdType="pubmed">36931201</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular docking, dynamics simulations, ADMET, and DFT calculations: combined in silico approach to screen natural inhibitors of 3CL and PL proteases of SARS‐CoV‐2. Mohanasundaram S, Karthikeyan P, Sampath V, et al.  https://onlinelibrary.wiley.com/doi/10.1155/2024/6647757 Cell Microbiol. 2024</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>